CellaVision AB
C26
Company Profile
Business description
CellaVision AB is engaged in the business of supplying digital solutions for blood and body fluid analysis. Its solutions are based on digital image analysis technology, artificial intelligence, and information technology. The firm's product portfolio consists of CellaVision peripheral blood application, CellaVision advanced RBC application, and CellaVision remote review software. Its customers include mainly large hospital laboratories and commercial laboratories in North America, Europe and China, and Japan. The company derives the majority of its revenue from the sale of analyzers or software.
Contact
Mobilvagen 12
Lund22362
SWET: +46 464601600
Sector
Healthcare
Stock type
Defensive
Industry
Medical Devices
Fiscal Year End
31 December 2025
Employees
249
Stocks News & Analysis
stocks
Cutting our fair value on ASX share after poor guidance
Our view after the shares stand after a 20% drop.
stocks
2 companies poised to capitalize on the rise of GLP-1 drugs
Why Pfizer and Roche look like top choices for investors in the war to tip the scales.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,868.20 | 33.10 | -0.37% |
| CAC 40 | 8,052.51 | 55.92 | -0.69% |
| DAX 40 | 24,162.65 | 116.64 | 0.49% |
| Dow JONES (US) | 47,560.29 | 179.03 | -0.38% |
| FTSE 100 | 9,642.01 | 3.08 | -0.03% |
| HKSE | 25,444.75 | 10.52 | 0.04% |
| NASDAQ | 23,576.49 | 30.58 | 0.13% |
| Nikkei 225 | 50,602.80 | 52.30 | -0.10% |
| NZX 50 Index | 13,371.06 | 83.72 | -0.62% |
| S&P 500 | 6,840.51 | 6.00 | -0.09% |
| S&P/ASX 200 | 8,579.40 | 31.70 | -0.37% |
| SSE Composite Index | 3,899.72 | 9.80 | -0.25% |